Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield and its partner, Viatris, have increased physician awareness of the differentiating characteristics of Accrufer® as an oral ID drug, in order to ramp up prescriptions (Rxs) and generate sales traction. Positive Rx momentum in 2022 and 2023, is expected to accelerate in 2024 and 2025 with the revised aim of becoming cashflow positive in 2H’25. This, coupled with extended financing options has obviated any requirement for a capital increase.
![working](/images/WorkingLarge.gif)
23 May 2024
Hardman & Co Research: Shield Therapeutics (STX): Cash management is key
![](/images/orange-lock.png)
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Hardman & Co Research: Shield Therapeutics (STX): Cash management is key
Shield Therapeutics Plc (STX:LON) | 2.0 0 0.0% | Mkt Cap: 16.0m
- Published:
23 May 2024 -
Author:
Martin Hall -
Pages:
17 -
Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield and its partner, Viatris, have increased physician awareness of the differentiating characteristics of Accrufer® as an oral ID drug, in order to ramp up prescriptions (Rxs) and generate sales traction. Positive Rx momentum in 2022 and 2023, is expected to accelerate in 2024 and 2025 with the revised aim of becoming cashflow positive in 2H’25. This, coupled with extended financing options has obviated any requirement for a capital increase.